Physician profile
Omar E Awad
NPI 1619942174
$6,112.34
in general payments reported to CMS, 2019-2025
10 companies · $282 in 2025
The $282 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,085 · 2021: $73.79 · 2022: $1,245 · 2023: $223 · 2024: $204 · 2025: $282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $709.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $709.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $3,613.75 | 2019 | |
| Kala Pharmaceuticals, INC. | $1,200.00 | 2022 | |
| Alcon Vision LLC | $799.65 | 2019-2025 | Acrysof Iq Vivity, Clareon, Argos |
| Glaukos Corporation | $160.40 | 2021-2025 | Kxl System (Not Refurbished), Photrexa Viscous and Photrexa |
| Ocular Therapeutix, INC. | $156.06 | 2019 | |
| Biotissue Holdings INC. | $110.78 | 2024-2025 | |
| Inspire Medical Systems, INC. | $24.72 | 2025 | Inspire |
| Oyster Point Pharma, INC. | $21.97 | 2023 | Tyrvaya |
| The Cameron-Ehlen Group, INC. | $13.86 | 2021 | |
| Sun Pharmaceutical Industries INC. | $11.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omar Awad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.